NEW YORK (TheStreet) -- Barclays downgraded C.R. Bard (BCR) to "equal weight" from "overweight." The firm noted pressure on the company due to its exposure to the peripheral vascular space affected by the Medtronic (MDT) deal with Covidien (COV).
The stock closed at $137.74 on Tuesday.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts